Search Results
Search results for "GIO Therapeutics"
Results found for "GIO Therapeutics"
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates | Dr. GPCR Ecosystem
development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- Stuart Maudsley: Receptor Complexity, Aging, and the Limits of Single Target Drugs | Dr. GPCR Ecosystem
signaling shifts across a lifetime, and how high dimensional data turns biological complexity into therapeutic combines mass spectrometry, natural language processing and topological data analysis to build GPCR based therapeutics More dimensions of signaling means more places a therapeutic can enter.
- Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares Therapeutics She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery
- Dr. Michael Feigin | Dr. GPCR Ecosystem
Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic
- Tuning GPCR System Sensitivity: Revealing True Drug Activity Through Functional Volume Control | Dr. GPCR Ecosystem
development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- Yao Lu (Jackie) | Dr. GPCR Ecosystem
molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics
- Tanishka S. Saraf | Dr. GPCR Ecosystem
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem
biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic
- Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński | Dr. GPCR Ecosystem
Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations
- The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem
She has advanced the use of computational methods to meet the challenges of designing therapeutics with
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Dr. Adriano Marchese | Dr. GPCR Ecosystem
The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic
- Why Mosquitoes Hunt You: GPCR Control of Blood Feeding and Mating | Dr. GPCR Ecosystem
response to human bias in the data - Vector behavior disruption as an alternative to pathogen specific therapeutics receptor could block all of these pathogens at their point of transmission, rather than requiring a therapeutic
- GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem
At Tectonic Therapeutic, his lab contributed to the discovery of the RXFP1 agonist TX45, and he led the Keeping GLP1 receptors at the membrane can shape the therapeutic profile Building on work from Stephen
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Timo De Groof | Dr. GPCR Ecosystem
nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic
- Yamina's Corner | Dr. GPCR Ecosystem
Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed
- Dr. Prasenjit Saha | Dr. GPCR Ecosystem
receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic
- Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem
Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. The goal is to test therapeutic strategies targeting the AT1R, alpha-adrenergic, and beta-adrenergic
- Visualizing GLP-1 & GIP Receptors in Islets and Brain | Dr. GPCR Ecosystem
neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid therapeutic This is not a quirk — it is the central clue the lab has built a therapeutic strategy around.
- Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics
- Kathryn Livingston: Allosteric Opioid Modulators and Receptor Signaling Beyond the Membrane | Dr. GPCR Ecosystem
Themes of the Conversation Allosteric modulation of opioid receptors - mechanism, selectivity, and therapeutic The therapeutic logic is that decoupling from the orthosteric site might preserve pain relief while altering
- Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes | Dr. GPCR Ecosystem
GPR56 as a mechanical sensor and his sustained case for the KLF2 signaling pathway as a GPCR-linked therapeutic His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics



























